Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9HB96
UPID:
FANCE_HUMAN
Alternative names:
-
Alternative UPACC:
Q9HB96; A8K907; Q4ZGH2
Background:
The Fanconi anemia group E protein plays a pivotal role in DNA repair, specifically in the process of DNA cross-links repair. It is essential for the nuclear accumulation of FANCC and acts as a bridge between the FA complex and FANCD2, highlighting its critical function in maintaining genomic stability.
Therapeutic significance:
Fanconi anemia complementation group E, a disorder linked to this protein, affects bone marrow elements leading to various malformations and a predisposition to malignancies. Understanding the role of Fanconi anemia group E protein could open doors to potential therapeutic strategies, especially in enhancing DNA repair mechanisms.